TP53 and cancer: Being the most frequently mutated gene in cancers, investigators have closely examined TP53 to determine its relationship with outcomes (Kadia et al., 2016; Robles and Harris, 2010; Said et al., 2013; Said et al., 2014; Schwaederlé et al., 2017; Solomon et al., 2018; Soussi, et al., 2006; Sun et al., 2018; Villaflor et al., 2016).